



ASTHMA 2024 GUIDELINES

CREATED BY DR NUSAIBA ALABBASI
Simplified clinic guide for **Primary Care**

SOURCE:
ASTHMA GUIDELINES
GINA GUIDELINES 2024



ASTHMA 2024 GUIDELINES



WHAT IS ASTHMA?



SOURCE:
GINA GUIDELINES 2024




What is Asthma

Chronic airway inflammation. Defined by the history **respiratory symptoms** that **vary** over in time and in intensity, together with variable expiratory airflow limitations



Approach to asthma

SUSPECTING ASTHMA?



- ✓ Recurrent wheeze, shortness of breath, chest tightness, and/or cough
- ✓ Symptoms vary over time and in intensity
- ✓ Worsen at night, on waking,
- ✓ Often triggered by exercise, laughter, exposure to allergens or cold air
- ✓ Appear or worsen with viral infections

CLINICAL ASSESSMENT

History

- ✓ Symptom frequency, timing (e.g., seasonal, nocturnal)
- ✓ **Triggers:** exercise, weather, pets, dust, smoke
- ✓ **Medication use and response** (e.g. relief with salbutamol)
- ✓ Sick days, emergency visits, previous diagnoses

Physical Examination

- ✓ May reveal wheezing, especially during forced expiration
- ✓ Often normal between attacks

CLINICAL CLUES



- ✓ Personal or family history of asthma, eczema, or allergic rhinitis
- ✓ Symptoms triggered by known allergens or irritants
- ✓ Response to bronchodilators

SOME DIFFERENTIAL DIAGNOSIS TO CONSIDER

Full detailed list available in GINA guideline page 27-28

- **COPD** ----- Older age, smoker, persistent symptoms, less reversibility
- **Heart failure** ----- Orthopnea, edema, cardiac history
- **GERD** ----- Cough after meals, heartburn
- **Upper airway cough syndrome** ----- Postnasal drip, throat clearing
- **Vocal cord dysfunction** ----- Inspiratory wheeze, no bronchodilator response

TESTING IN PRIMARY CARE CLINIC SETTING

Using Peak Expiratory Flow meter (PEF)

Bronchodilator (BD) reversibility test with PEF

1. Measure PEF in clinic
2. Give 200-400 mcg salbutamol
3. Measure change 10-15 minutes after and compare with pre-BD readings



✓ **Adults:** increase in PEF $\geq 20\%$

✓ **Children:** increase in PEF $\geq 15\%$



Note: Positive test more likely if BD withheld before test: SABA ≥ 4 hours, LABA 24-48 hours

Other tests to consider

Excessive variability in BD PEF over 2 weeks



✓ **Adults:** average daily diurnal PEF variability $> 10\%$

✓ **Children:** average daily diurnal PEF variability $> 13\%$

Increase in Lung function after 4 weeks of treatment



✓ **Adults:** increase in PEF $\geq 20\%$

✓ **Children:** increase in PEF $\geq 15\%$

CONFIRMING THE DIAGNOSIS

A diagnosis of asthma is confirmed when:

- ✓ Typical symptoms are present
 - ✓ Variable expiratory airflow limitation is documented
 - ✓ Alternative diagnoses have been excluded
- Repeat testing may be needed over time if initial results are inconclusive.

GENERAL PRINCIPLES



FOLLOW UP

- After initiation ➤ **Every 1-3 months**
- If stable with good inhaler technique ➤ **Every 3-12 months**
- After Exacerbation ➤ **Follow up in 1 week**




STEPPING UP

Sustained (symptoms persist despite 2-3 months of controller)

- Assess Inhaler technique
- Modifiable risk Factors
- Poor Adherence
- Other conditions causing symptoms (e.g. *allergic rhinitis*)

Short term step up

- For **1-2 weeks** if viral infection or allergen exposure



STEPPING DOWN

If symptoms controlled for ≥ 3 months; consider:

- Good timing (*no URTI, not pregnant, not travelling*)
- Assess Frequency of exacerbations and ER visits
- Document baseline status
- Provide written asthma plan if available
- Reduce ICS dose by **25-50% gradually** on **2-3 months** interval
 - e.g. If on low dose ICS Symbicort PRN





Summary of assessment of asthma in adults, adolescents, and children 6–11 years



Assess asthma
control



Assess
treatment issues



Assess
multimorbidity

SYMPTOM CONTROL & FUTURE RISK OF ADVERSE OUTCOMES

- **ASSESS** symptom control over the last 4 weeks or longer.
- **IDENTIFY** risk factors for exacerbations, persistent airflow limitation or side-effects
- **MEASURE** lung function:
 - At diagnosis/start of treatment,
 - 3–6 months after starting ICS-containing treatment
 - Then periodically
 - e.g., \geq every 1–2 years, but more often in at-risk patients and those with severe asthma.



ASSESS TREATMENT ISSUES

- **DOCUMENT** the patient's current treatment step
- **WATCH** inhaler technique, assess adherence and side-effects
- **CHECK** that the patient has a written asthma action plan.
- **ASK** about the patient's attitudes and goals for their asthma and medications.

ASSESS MULTIMORBIDITY

- Rhinitis, rhinosinusitis, GERD, obesity, OSA, depression and anxiety can contribute to symptoms and poor quality of life, and sometimes to poor asthma control

ASTHMA 2024 GUIDELINES



ADULT & ADOLESCENT



SOURCE:
GINA GUIDELINES 2024

STEP ➤ 1



Infrequent asthma symptoms ≤ 2 days/week

TRACK 1

AIR ONLY

Low dose ICS + LABA PRN

Symbicort

(Budesonide/Formoterol)

160mcg/4.5mcg



1 inhalation PRN

Max 12 inhalations/day

Budesonide
Low dose = 200-400/day

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN

Max 8 puffs/day

+

CONTROLLER

Low dose ICS whenever SABA is taken

Flixotide

(Fluticasone Propionate)

125mcg



1 puff PRN

Max 8 puffs/day

Fluticasone propionate
Low dose = 100-250/day

STEP ➤ 2



Asthma symptoms $< 3-5$ times/week
with normal or mildly reduced Lung Function Test

➤ Start at STEP 2
for most adults &
adolescents

TRACK 1

AIR ONLY

Low dose ICS + LABA PRN

Symbicort

(Budesonide/Formoterol)

160mcg/4.5mcg



1 inhalation PRN

Max 12 inhalations/day

Budesonide
Low dose = 200-400/day

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN

Max 8 puffs/day

+

CONTROLLER

Low dose ICS daily maintenance

Flixotide

(Fluticasone Propionate)

125mcg



1 puff once daily

Max 8 puffs/day

Fluticasone propionate
Low dose = 100-250/day

STEP ➤ 3



Symptoms most days or night time ≥ 1 time/week or Low PFT

TRACK 1

AIR ONLY

Low dose ICS daily + PRN

Symbicort

(Budesonide/Formoterol)

160mcg/4.5mcg



1 inhalation BD + PRN

Max 12 inhalations/day

Budesonide
Low dose = 200-400/day

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN

Max 8 puffs/day

CONTROLLER

Low dose ICS-LABA daily maintenance

Seretide

(Fluticasone/Salmeterol)

250mcg



1 inhalation OD

250mcg/50mcg

Fluticasone propionate
Low dose = 100-250/day

Relvar

(Fluticasone/vilanterol)

100mcg



1 inhalation OD

100mcg/25mcg

Fluticasone Furate
Low dose = 100/day

+

OR

STEP ➤ 4



Daily symptoms or night time ≥ 1 time/week with Low PFT

TRACK 1

AIR ONLY

Medium dose ICS daily + PRN

Symbicort

(Budesonide/Formoterol)

160mcg/4.5mcg



2 inhalations BD + PRN

Max 12 inhalations/day

Budesonide
Medium dose = 400-800/day

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN

Max 8 puffs/day

CONTROLLER

Medium dose ICS-LABA daily maintenance

Seretide

(Fluticasone/Salmeterol)

500mcg



1 inhalation OD

500mcg/50mcg

Fluticasone propionate
Medium dose = 250-500/day

Relvar

(Fluticasone/vilanterol)

100mcg



1 inhalation OD

100mcg/25mcg

Fluticasone Furate
Medium dose = 100/day

+

OR

STEP 5

Uncontrolled Symptoms
and/or exacerbations despite STEP4 treatment



REFER TO SECONDARY CARE

- Consider add-on therapy including **LAMA** (e.g. **TRELEGY**)
- Step-Up treatment

TRACK 1

AIR ONLY

High dose ICS daily + PRN

Symbicort

(Budesonide/Formoterol)
160mcg/4.5mcg



4 inhalation BD + PRN
Max 12 inhalations/day

Budesonide
High dose = > **800/day**

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN
Max 8 puffs/day

CONTROLLER

High dose ICS-LABA daily maintenance

Seretide

(Fluticasone/Salmeterol)
500mcg



1 inhalation OD
500mcg/50mcg

Fluticasone propionate
High dose = > **500/day**

Relvar

(Fluticasone/vilanterol)
200mcg



1 inhalation OD
200mcg/25mcg

Fluticasone Furoate
High dose = **200/day**



Trelegy

Contains 3 long-acting medicines:

- Fluticasone furoate (**ICS**)
- Umeclidinium (**LAMA**)
- Vilanterol (**LABA**)



ASTHMA 2024 GUIDELINES



CHILDREN 6-11 YEARS



SOURCE:
GINA GUIDELINES 2024

STEP ➤ 1

Infrequent asthma symptoms ≤ 1 -2 days/week



RELIEVER

SABA PRN

Ventolin
(Salbutamol)



+

CONTROLLER

Low dose ICS whenever SABA is taken or daily

Flixotide

(Fluticasone Propionate)
50mcg



OR

Pulmicort

(Budesonide)
100mcg



1-2 puffs PRN
Max 4 puffs/day

1 puff BD or PRN
Max 8 puffs/day

Fluticasone propionate
Low dose = 50-100/day

1 inhalation BD or PRN
Max 7 puffs/day

Budesonide
Low dose = 100-200/day

STEP ➤ 2

Asthma symptoms 2-5 days/week



RELIEVER

SABA PRN

Ventolin
(Salbutamol)



+

CONTROLLER

Low dose ICS whenever SABA is taken or daily

Flixotide

(Fluticasone Propionate)
50mcg



OR

Pulmicort


(Budesonide)
100mcg



OR

Singulair

(Montelukast)
5mg



1-2 puffs PRN
Max 4 puffs/day

1 puff BD
Max 8 puffs/day

Fluticasone propionate
Low dose = 50-100/day

1 inhalation BD
Max 7 puffs/day

Budesonide
Low dose = 100-200/day

5mg OD
Chewable

STEP ➤ 3



Symptoms most days or night time ≥ 1 time/week

TRACK 1

AIR ONLY

Low dose ICS daily + PRN

Symbicort

(Budesonide/Formoterol)

80mcg/4.5mcg



1 inhalation BD + PRN
Max 8 inhalations/day

Budesonide
Low dose = 100-200/day

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN
Max 4 puffs/day

CONTROLLER

Low dose ICS-LABA daily

Seretide

(Fluticasone/Salmeterol)

100mcg



1 inhalation BD
100mcg/50mcg

Fluticasone propionate
Low dose = 50-100/day

Medium dose ICS daily

Flixotide

(Fluticasone Propionate)

100mcg



1 puff BD

Fluticasone propionate
Medium dose = 100-200/day

Pulmicort

(Budesonide)

100mcg



2 inhalation BD

Budesonide
Medium = 200-400/day

STEP ➤ 4



Daily symptoms or night time ≥ 1 time/week with Low PFT

TRACK 1

AIR ONLY

Low dose ICS daily + PRN

Symbicort

(Budesonide/Formoterol)

80mcg/4.5mcg



1 inhalations BD + PRN
Max 8 inhalations/day

Budesonide
Medium dose = 100-200/day

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN
Max 4 puffs/day

CONTROLLER

Medium dose ICS-LABA daily maintenance + LTRA

Seretide

(Fluticasone/Salmeterol)

100mcg




1 inhalation BD
100mcg/50mcg

Fluticasone propionate
Medium dose = 100-200/day

Singulair

(Montelukast)

5mg



5mg OD
Chewable

STEP 5

Uncontrolled Symptoms
and/or exacerbations despite STEP4 treatment



REFER TO SECONDARY CARE

- Consider add-on therapy including **LAMA**
- Step-Up treatment

TRACK 1

AIR ONLY

High dose ICS daily + PRN

Symbicort

(Budesonide/Formoterol)
80mcg/4.5mcg



2 inhalation BD + PRN
Max 8 inhalations/day

Budesonide
High dose = > 400/day

TRACK 2

RELIEVER

SABA PRN

Ventolin

(Salbutamol)



1-2 puffs PRN
Max 4 puffs/day

CONTROLLER

High dose ICS-LABA daily maintenance + LTRA

Seretide

(Fluticasone/Salmeterol)
100mcg




2 inhalation BD
100mcg/50mcg

Fluticasone propionate
High dose = >200/day

Singulair

(Montelukast)
5mg



5mg OD
Chewable

Don't Forget!

ASSESSING ASTHMA SYMPTOM CONTROL

In adults, adolescents and children 6-11 years

In the past 4 weeks (or since last review) has the patient had:

Daytime asthma symptoms more than twice/week?

☐ Yes ☐ No

Any **night waking** due to asthma?

☐ Yes ☐ No

SABA reliever for symptoms more than twice/week?

☐ Yes ☐ No

Any **activity limitation** due to asthma?

☐ Yes ☐ No



Well controlled
none = 0

Partly controlled
1-2 of these

Uncontrolled
3-4 of these



ASTHMA 2024 GUIDELINES



ASTHMA MEDICATIONS **GLOSSARY**



SOURCE:
GINA GUIDELINES 2024

ASTHMA MEDICATIONS GLOSSARY



VENTOLIN Salbutamol

RELIEVER

SABA - SHORT ACTING BETA AGONIST




EVOHALER

- ≥ 4 years
- **100mcg**
- **Adults:** Max **8 puffs/day** (800mcg)
- **Children:** Max **4 puffs/day** (400 mcg)
- Capacity: 200 doses/canister



DISKUS

- ≥ 4 years
- **200mcg**
- Maximum: **4 puffs/day**
- Capacity: 60 doses/device



NEBULES

- ≥ 2 years and **>10 Kg**
- **2.5mg** in 2.5mL
- Every **4-6 hours** as needed
- **Dilute** in 2mL NS
- 2-12 years: max **4-6 doses/day**



NEBULES

- ≥ 12 years
- **5mg** in 2.5 mL
- Every **4-6 hours** as needed
- ≥ 12 years: max **4 doses/day**



FLIXOTIDE

Fluticasone propionate

CONTROLLER

ICS - INHALED CORTICOSTEROID



EVOHALER

- ≥ 1 year
- **Twice Daily (BID)**
- **50mcg, 125mcg, 250mcg**
- Maximum: 2000mcg/day
- Capacity: 120 doses/canister



DISKUS

- ≥ 4 years
- **50mcg, 100mcg, 250mcg, 500mcg**
- Maximum: 2000mcg/day
- Capacity: 60 doses/device

DAILY MAXIMUM DOSE

ADULTS & ADOLESCENTS

Low	Medium	High
100-250	> 250-500	> 500

CHILDREN 6-11 YEARS

Low	Medium	High
50-100	> 100-200	> 200

< 2 YEARS OLD

50mcg BD



PULMICORT Budesonide


CONTROLLER

ICS - INHALED CORTICOSTEROID




TURBOHALER

- ≥ 6 year
- **Twice Daily (BID)**
- **100mcg, 200mcg, 400mcg**
- Maximum: 2400mcg/day
- Capacity: 200 doses/canister



NEBULES

- ≥ 1 year
- **0.25mg/2mL**
- No dilution required
- Maximum: **1mg/day**



NEBULES

- ≥ 1 year
- **0.5mg/2mL**
- No dilution required
- Maximum: **1mg/**
- Adults max 2mg/day

DAILY MAXIMUM DOSE

ADULTS & ADOLESCENTS

Low	Medium	High
200-400	> 400-800	> 800

CHILDREN 6-11 YEARS

Low	Medium	High
100-200	> 200-400	> 400

ASTHMA MEDICATIONS GLOSSARY



SYMBICORT

Budesonide + Formoterol

CONTROLLER

COMBINATION ICS + LABA



SMART

Single Maintenance & Reliever Therapy.

TURBOHALER

- ≥ 6 years
- PRN, OD or BID
- **80mcg/4.5mcg** (60 doses/device)
- **160mcg/4.5mcg** (120 doses/device)
- Maximum: **8 inhalations per day**

DAILY MAXIMUM DOSE

ADULTS & ADOLESCENTS

Low	Medium	High
200-400	> 400-800	> 800

CHILDREN 6-11 YEARS

Low	Medium	High
100-200	> 200-400	> 400



SERETIDE

Fluticasone propionate + Salmeterol

CONTROLLER

COMBINATION ICS + LABA



EVOHALER

- ≥ 4 year
- **Twice Daily (BID)**
- **50mcg, 125mcg, 250mcg**
- Maximum: 1000mcg/day



DISKUS

- ≥ 4 years
- **Twice Daily (BID)**
- **100mcg, 250mcg, 500mcg**
- Maximum: 2000mcg/day (adults)
- Capacity: 60 doses/device

DAILY MAXIMUM DOSE

ADULTS & ADOLESCENTS

Low	Medium	High
100-250	> 250-500	> 500

CHILDREN 6-11 YEARS

Low	Medium	High
50-100	> 100-200	> 200



RELVAR

Fluticasone Furoate + Vilanterol

CONTROLLER

COMBINATION ICS + LABA



- ≥ 12 year
- **Once Daily (OD)**
- **100mcg/25mcg, 200mcg/25mcg**
- Maximum: 200mcg/day
- Capacity: 30 doses/canister

ELLIPTA

DAILY MAXIMUM DOSE

ADULTS & ADOLESCENTS

Low	Medium	High
100	100	200

ASTHMA MEDICATIONS GLOSSARY



TRELEGY

Fluticasone Furoate + Vilanterol + Umeclidinium

CONTROLLER

COMBI. ICS + LABA + LAMA



- ≥ 12 year
- Once Daily (OD)
- 100mcg, 200mcg
- Maximum: 200mcg/day
- Capacity: 30 doses/canister

ELLIPTA

DAILY MAXIMUM DOSE

ADULTS & ADOLESCENTS

Low	Medium	High
100	100	200



SINGULAIR MONTELUKAST

CONTROLLER

ORAL ADD-ON TREATMENT

USE

- **Asthma:** ≥ 1 year
- **EIB*:** ≥ 6 years
- **Allergic rhinitis:**
 - **Seasonal:** ≥ 2 years
 - **Perennial:** ≥ 6 months



TIMING/FREQUENCY

- **Asthma:** once daily, in the evening
- **EIB*:** once daily, at least 2 hours before exercise
- **Allergic rhinitis:** once daily, morning or evening

FORMS

TABLETS

≥ 15 years 10mg once daily HS in the evening

CHEWABLE

≥ 6 years 5mg once daily in the evening

ORAL GRANULES

≥ 1 year 4mg once daily in the evening

*Exercise induced asthma


Don't Forget !

MINIMIZE ADVERSE EFFECTS OF MEDICATION

Reduce the potential for local and/or systemic side-effects of inhaled medications by:

- Ensuring correct inhaler technique
- Reminding patients to **rinse and spit out** after using ICS
- Finding each patient's **minimum effective dose of ICS-containing therapy**
 - the lowest dose that will, in conjunction with an action plan, maintain good symptom control and minimize exacerbations

ASTHMA 2024 GUIDELINES



PRIMARY CARE MANAGEMENT OF **EXACERBATION**

Adults, adolescents, children 6-11 years



SOURCE:
GINA GUIDELINES 2024

CHECK SEVERITY



Measure

- ☐ Ability to speak
- ☐ Use of accessory muscles
- ☐ Respiratory Rate (RR)
- ☐ O₂ Saturation (SpO₂) on RA
- ☐ PEF; if possible

Mild-Moderate

- Talks in phrases
- Prefers sitting to lying
- Not agitated
- RR increased
- Accessory muscles not used
- HR 100-120 bpm
- SpO₂ on RA 90-95%
- PEF > 50% predicted or best



Severe

- Talks in words
- Sits hunched forwards
- Agitated
- RR >30/min
- Accessory muscles in use
- HR > 120 bpm
- SpO₂ on RA < 90%
- PEF ≤ 50% predicted or best



Life-threatening

- Drowsy
- Confused
- or silent chest



Start treatment immediately
do not delay while assessing

Check for asthma-related death factors:

- ☐ History of near-fatal asthma requiring intubation.
- ☐ Hospital or ER visit for asthma in the past year.
- ☐ Recent or current use of oral corticosteroids.
- ☐ Not using ICS
- ☐ Overuse of SABAs (*e.g.*, >1 salbutamol canister/month or nebulized use).
- ☐ Poor adherence to ICS or lack of an asthma action plan.
- ☐ History of psychiatric or psychosocial issues.
- ☐ Food allergy with asthma.
- ☐ Multiple comorbidities (*e.g.*, pneumonia, diabetes, arrhythmias).



PRIMARY CARE MANAGEMENT OF EXACERBATION

STEP 1

OXYGEN

- if needed



Target SpO₂: **93–95%**

- Nasal cannula: **≤ 6 L/min**
- Face mask: **6-10 L/min**



Target SpO₂: **≥ 94%**

- Nasal Cannula: **1-2 L/min**
- Face mask: **6-10 L/min**

STEP 2

SABA

- via nebulizer
VENTOLIN



≥ 12 years

5mg

Max. **20-30 mg/day**



2-12 years

2.5mg

Max. **20-30 mg/day**



< 2 years

1.25mg

Max. **10-12.5 mg/day**



🕒 **Every 20 minutes x3 doses, then q1–4 hours PRN**

▶ **Nebulize with 2–3 mL of normal saline**

STEP 3

SAMA

- via nebulizer
ATROVENT

Combine with SABA during moderate–severe exacerbations



≥ 6 years & adults

0.5mg (1 mL of 0.02%)

Max. **2-3 mg/day**



1-5 years

0.25mg (0.5 mL of 0.02%)

Max. **1-2 mg/day**




🕒 **Every 20 minutes x3 doses, then q1–4 hours PRN**

▶ **Nebulize with 2–3 mL of normal saline**

STEP 4

CONTRCOSTEROIDS

ORAL CS in **moderate** exacerbations and IV CS in **severe** cases



ADULTS

Prednisone PO

40-50 mg OD

⌚ Duration: 5-7 days

Methylprednisolone IV

60-80 mg/day



CHILDREN

Prednisolone PO

1-2 mg/kg (max 40 mg)

⌚ Duration: 5-7 days

Methylprednisolone IV

1-2 mg/kg/day

STEP 5

REFER to ER



Poor response



< 90-92%



Very tired





Silent chest



- ☐ Poor response to initial treatment
- ☐ SpO₂ remains < 90-92% despite oxygen
- ☐ Unable to speak in full sentences or very tired
- ☐ Silent chest, cyanosis, or altered consciousness

STEP 6

FOLLOW UP



Action Plan



Inhaler Use



Maintenance therapy

- ☐ Ensure patient has an asthma action plan
- ☐ Educate on inhaler use and trigger avoidance
- ☐ Review maintenance therapy (e.g., ICS)

Guided by evidence, Shared by heart.

From a passionate family medicine
physician to another.

📷familymedguide - Dr Nusaiba AlAbbasi



REFERENCE.
GINA GUIDELINES 2024